In the last trading session, 3.2 million ATAI Life Sciences N.V (NASDAQ:ATAI) shares changed hands as the company’s beta touched 1.49. With the company’s per share price at $2.28 changed hands at -$0.13 or -5.39% during last session, the market valuation stood at $457.72M. ATAI’s last price was a discount, traded about -15.79% off its 52-week high of $2.64. The share price had its 52-week low at $1.03, which suggests the last value was 54.82% up since then.
Analysts gave the ATAI Life Sciences N.V (ATAI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ATAI as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. ATAI Life Sciences N.V’s EPS for the current quarter is expected to be -0.1.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
Instantly ATAI was in red as seen at the end of in last trading. With action -8.43%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 71.43%, with the 5-day performance at -8.43% in the red. However, in the 30-day time frame, ATAI Life Sciences N.V (NASDAQ:ATAI) is 62.86% up.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 54.4% from its current market value. According to analyst projections, ATAI’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -119.3% plunge from its current level, while the stock would need to soar -119.3% for it to hit the projected low.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
Year-over-year growth is forecast to reach 338.54% up from the last financial year.
The company’s revenue for the corresponding quarters a year ago was 273k and 40k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -100.00%. The estimates for the next quarter sales put growth at -100.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 18.62%. The 2025 estimates are for ATAI Life Sciences N.V earnings to increase by 43.32%, but the outlook for the next 5-year period is at 29.49% per year.
ATAI Dividends
ATAI Life Sciences N.V is expected to release its next quarterly earnings report in July.
MORGAN STANLEY holds the second largest percentage of outstanding shares, with 1.6952% or 2.72 million shares worth $3.62 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were MORGAN STANLEY INSTITUTIONAL FUND INC-Inception Portfolio and AdvisorShares Trust-AdvisorShares Psychedelics ETF . With 511.99 shares estimated at $1.17 million under it, the former controlled 0.26% of total outstanding shares. On the other hand, AdvisorShares Trust-AdvisorShares Psychedelics ETF held about 0.21% of the shares, roughly 415.76 shares worth around $0.95 million.
